Advaxis to Be Featured on Worldwide Business with kathy ireland®
June 14 2017 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company
developing cancer immunotherapies, today announced that Advaxis
will be featured on Worldwide Business with kathy ireland®
on Sunday, June 18. The 30-minute segment, available on Youtube,
includes interviews with Daniel J. O’Connor, President and Chief
Executive Officer of Advaxis; Robert Petit, PhD, Chief Scientific
Officer; Sara Bonstein, Chief Financial Officer; and Brian
Slomovitz, MD, Director of the Division of Gynecologic Oncology in
the Department of Obstetrics and Gynecology at the University of
Miami Miller School of Medicine.
The episode airs on Fox Business Network as sponsored
programming at 5:30 p.m. ET / 2:30 p.m. PT (check your local
listings) and on Bloomberg International at 10:30 a.m. CT. For more
information on Worldwide Business with kathy ireland, visit
http://www.tvwwb.com/.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a late-stage
biotechnology company developing multiple cancer immunotherapies
based on its proprietary Lm Technology. Lm Technology,
using bioengineered live attenuated Listeria
monocytogenes (Lm) bacteria, is the only known cancer
immunotherapy agent shown in preclinical studies to both generate
cancer fighting T cells directed against cancer antigens and
neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that
protect the tumor microenvironment from immunologic attack and
contribute to tumor growth. Advaxis’ lead Lm Technology™
immunotherapies axalimogene filolisbac and ADXS-DUAL target
HPV-associated cancers and are in clinical trials for invasive and
metastatic cervical cancer, head and neck cancer and anal cancer.
The FDA has granted axalimogene filolisbac orphan drug designation
for each of these three clinical settings, as well as Fast Track
designation for adjuvant therapy for HRLACC patients and a SPA for
the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene
filolisbac has also been classified as an advanced therapy
medicinal product for the treatment of cervical cancer by the EMA’s
CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in
prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in
human clinical development. In addition, Advaxis and Amgen are
developing ADXS-NEO, an investigational cancer immunotherapy
treatment designed to activate a patient's immune system to respond
against the unique mutations, or neoepitopes, contained in and
identified from each individual patient's tumor, with plans to
enter the clinic in 2017.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop the next generation of cancer immunotherapies,
and the safety and efficacy of Advaxis’ proprietary
immunotherapies, axalimogene filolisbac and ADXS-DUAL. These
forward-looking statements are subject to a number of risks
including the risk factors set forth from time to time in Advaxis’
SEC filings including, but not limited to, its report on Form 10-K
for the fiscal year ended October 31, 2016, which is available at
http://www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law.
You are cautioned not to place undue reliance on any
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170614005555/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
Affairsheber@advaxis.comorMedia Contact:JPA Health
CommunicationsDavid Connolly, 617-657-1301dconnolly@jpa.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024